Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Squamous Head and Neck Carcinoma: early-phase trial registry

1 of 1 indexed Squamous Head and Neck Carcinoma trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

Squamous Head and Neck Carcinoma: 1 US clinical trial tracked, 1 recruiting.

Squamous Head and Neck Carcinoma is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is GV20 Therapeutics, running 1 of these trials.

Enrollment posture brief

Registry condition squamous-head-and-neck-carcinoma

OPEN 1 | RECR 100% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Squamous Head and Neck C (th…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Squamous Head and Neck Carcinoma

Squamous Head and Neck Carcinoma lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Squamous Head and Neck Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Squamous Head and Neck Carcinoma is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11

Phase Distribution

PhaseTrial count
Phase 1 1

Top Sponsors

Named interventions

Most-linked intervention names on Squamous Head and Neck Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

GV20-0251 and Pembrolizumab [KEYTRUDA®] Biological
1 trials
GV20-0251 Biological
1 trials

US sites by state

Facility locations filed on Squamous Head and Neck Carcinoma trials. A trial with sites in several states counts in each.

Virginia 1 trials
Texas 1 trials
Tennessee 1 trials
Oregon 1 trials
New York 1 trials
Michigan 1 trials
Massachusetts 1 trials
Indiana 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Squamous Head and Neck Carcinoma page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 Squamous Head and Neck Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • GV20 Therapeutics sponsors the most Squamous Head and Neck Carcinoma trials on record, review their full trial history before evaluating a specific study. See GV20 Therapeutics's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Squamous Head and Neck Carcinoma condition card totals 1 registered trials; most-linked intervention GV20-0251 and Pembrolizumab [KEYTRUDA®]; top US site state Virginia. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.